SSP075 Monomil® XL 60mg modified-release tablet
The Department of Health and Social Care (DHSC) has issued a Serious Shortage Protocol (SSP) for Isosorbide Mononitrate (Monomil® XL) 60mg MR tablets in response to a significant ongoing supply disruption.
This SSP will enable community pharmacists in England, Wales, Scotland and Northern Ireland to supply patients with a different product as per the document below.
It allows an alternative medicine from the list below to be supplied against prescriptions for Monomil® XL 60mg MR tablets. The pharmacist must exercise their professional judgement to ensure the alternative product is suitable for the patient.
- Isosorbide mononitrate (Isotard® 60XL) 60mg modified-release tablet
- Isosorbide mononitrate (Medomon® XL) 60mg modified-release tablet
- Isosorbide mononitrate (Relosorb® XL) 60mg modified-release tablet
- Isosorbide mononitrate (Tardisc®XL 60) 60mg modified-release tablet
The choice of product is based on supply volumes and not clinical interchangeability. The total quantity supplied under this protocol should be equivalent to the number of days supplied on the original prescription.
SSP075 for Monomil® XL 60mg MR tablets will be in operation from Friday 6th September 2024 until Friday 17th January 2025.
Please note that the SSP may be amended or revoked at any time, so contractors must ensure that the SSP is still valid before each supply.